List view / Grid view
NICE has recommended that Ultomiris (ravulizumab) be available on the…
NICE has recommended that Ultomiris (ravulizumab) be available on the NHS for patients with paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome.
On the NICE’s recommendation, ravulizumab will be made available to…
On the NICE’s recommendation, ravulizumab will be made available to hundreds of patients with paroxysmal nocturnal haemoglobinuria on the UK’s NHS.
The recommendation will allow more data to be collected about…
The recommendation will allow more data to be collected about the combination treatment while allowing patients with high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer to access the medication.
Carfilzomib with dexamethasone and lenalidomide could be offered to approximately…
Carfilzomib with dexamethasone and lenalidomide could be offered to approximately 2,000 NHS patients as a second line treatment for multiple myeloma.
AstraZeneca’s Calquence (acalabrutinib), a chemotherapy-free monotherapy, will be offered to…
AstraZeneca’s Calquence (acalabrutinib), a chemotherapy-free monotherapy, will be offered to patients with chronic lymphocytic leukaemia.
Zolgensma, a one-off, potentially curative treatment for type 1 spinal…
Zolgensma, a one-off, potentially curative treatment for type 1 spinal muscular atrophy, is set to become the most expensive drug ever approved for use on the UK’s NHS.
Pembrolizumab with pemetrexed and platinum chemotherapy has been recommended by…
Pembrolizumab with pemetrexed and platinum chemotherapy has been recommended by NICE to treat non-squamous, non-small cell lung cancer.
NICE has recommended that the CAR T-cell therapy Tecartus be…
NICE has recommended that the CAR T-cell therapy Tecartus be given to patients with relapsed or refractory mantle cell lymphoma.
More than 1,000 people each year could benefit from treatment…
More than 1,000 people each year could benefit from treatment with a combination of venetoclax and obinutuzumab, according to NICE.
The regulatory body said that due to uncertainties surrounding the…
The regulatory body said that due to uncertainties surrounding the long-term effectiveness of nivolumab (Opdivo), its cost-effectiveness estimates are too high.
Liraglutide (Saxenda) will be offered to adults with non-diabetic hyperglycaemia…
Liraglutide (Saxenda) will be offered to adults with non-diabetic hyperglycaemia and a high risk of cardiovascular disease.
Bavencio (avelumab) and Inlyta (axitinib) are recommended by NICE for…
Bavencio (avelumab) and Inlyta (axitinib) are recommended by NICE for the treatment of advanced renal cell carcinoma, available on the Cancer Drugs Fund.
NICE has decided to not recommend Mayzent (siponimod) for use…
NICE has decided to not recommend Mayzent (siponimod) for use on the NHS as a secondary progressive multiple sclerosis treatment because its clinical trial did not directly compare it to interferon beta-1b.
Larotrectinib has been given a positive opinion by NICE, following…
Larotrectinib has been given a positive opinion by NICE, following the submission of a revised price after it was previously rejected.
The UK’s National Institute for Health and Care Excellence, NICE,…
The UK’s National Institute for Health and Care Excellence, NICE, recommends the use of fremanezumab on the NHS for preventing chronic migraine.
